Crucell and AERAS Announce Start of Tuberculosis Vaccine Clinical Trial

27-Oct-2006

Crucell N.V. announced that it has started the phase I clinical trial of the AdVac®-based tuberculosis vaccine it is developing in partnership with The AERAS Global TB Vaccine Foundation. The clinical trial will be an open-label study that will test the vaccine in a dose-escalation trial involving 24 healthy volunteers. The Phase I trial will be funded and managed by Aeras through a contract research Organization (CRO), PRA Clinical Pharmacology Center in Lenexa, Kansas, USA. The main parameters under examination will be safety, tolerability and immunogenicity.

According to the company, the second-generation Ad35 vector applied in the Crucell-Aeras TB program is extremely suitable for vaccine production on PER.C6® cell culture at scale. The production scale potential of the PER.C6® cell line has been demonstrated in an unprecedented successful bioreactor run of 20,000 liters. Such highly productive systems are particularly important in the case of poverty-related diseases such as HIV, malaria and TB, when 10-100 millions of doses need to be manufactured while keeping costs relatively low.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances